Tissue Acquisition, Processing, and Pathology (TAPP) Core

组织采集、处理和病理学 (TAPP) 核心

• 批准号: 8677704
• 负责人: MICHAEL D KALOS
• 金额: $ 12.65万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8677704
• 关键词: Anatomy; Antigens; Archives; Biological Assay; Biological Markers; Cell Line; Cessation of life; Chest; Clinical; Clinical Trials; Diagnosis; Enrollment; Goals; Ice; Instruction; Interferon-alpha; Interferons; Malignant Neoplasms; Neoplasm Antibodies; Operative Surgical Procedures; Pathologic; Pathologist; Pathology; Pathology processes; Patients; Process; Role; Sampling; Serological; Serum; Specimen; Specimen Handling; Tissues; Tumor Antigens; Tumor-Derived; immuno-gene therapy; mesothelin; neutralizing antibody; stable cell line; tumor

PROJECT SUMMARY (See instructions): The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are: A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens. B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1). C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1) D. Tissue acquisition (with Projects 1, 2 and 3). E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3). F. Assist in immunohistochemical analyses Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.

项目摘要（参见说明）： 组织采集、处理和病理学核心的目标是： A. 审查和分析临床试验患者（项目 1）的病理标本，包括间皮素水平和潜在的其他肿瘤抗原的表达。 B. 处理和存档正在进行和计划的临床试验（项目 1）的临床标本。 C 对干扰素-α、抗腺病毒中和抗体、血清间皮素和抗肿瘤抗体进行测定（使用项目 1） D. 组织采集（项目 1、2 和 3）。 E. 从源自临床试验受试者和其他手术患者的肿瘤建立稳定细胞系（项目 1、2 和 3）。 F. 协助免疫组化分析 由于卡罗尔博士不幸去世，迈克尔·卡洛斯博士将担任 TAPP 核心主任。委员会认证的解剖病理学家 Leslie Litzky 博士将专注于目标 A，并继续担任指定参考病理学家的角色，以便在患者参加临床试验之前确认诊断，并审查肿瘤样本上的间皮素或其他抗原表达。 Steven Albelda 博士 执行修订后的目标 C（先前建立的血清学测定）和 E（细胞系建立）所需的专业知识将有助于这一核心。